Liminal BioSciences Inc. (LMNL)
| Market Cap | 13.99M |
| Revenue (ttm) | 343,651 |
| Net Income (ttm) | 17.31M |
| Shares Out | 31.04M |
| EPS (ttm) | 0.57 |
| PE Ratio | 0.79 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 54,363 |
| Open | 0.451 |
| Previous Close | 0.451 |
| Day's Range | 0.450 - 0.460 |
| 52-Week Range | 0.365 - 4.180 |
| Beta | 1.54 |
| Analysts | Sell |
| Price Target | 2.04 (+352.5%) |
| Earnings Date | May 16, 2022 |
About LMNL
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein c... [Read more...]
Analyst Forecast
According to 7 analysts, the average rating for LMNL stock is "Sell." The 12-month stock price forecast is 2.04, which is an increase of 352.53% from the latest price.
News
Liminal BioSciences Announces Voting Results of its 2022 Annual General Meeting of Shareholders
LAVAL, QC and CAMBRIDGE, England , June 6, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General Meeti...
Liminal BioSciences Announces First Subject Dosed in Phase 1a Single Ascending Dose Clinical Trial of Fezagepras
LAVAL, QC and CAMBRIDGE, England , May 23, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today announced that the first subject has been dosed in ...
Liminal BioSciences Inc. (LMNL) Could Find Support Soon, Here's Why You Should Buy the Stock Now
Liminal BioSciences Inc. (LMNL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions c...
Liminal BioSciences Reports First Quarter 2022 Financial Results and Business Highlights
Planned Phase 1a Single Ascending Dose ("SAD") clinical trial of fezagepras expected to commence in Q2 2022 Completion of analysis of safety and pharmacokinetic ("PK") data from Phase 1 Multiple Ascendi...
Liminal BioSciences to Report First Quarter 2022 Financial Results on May 10, 2022
LAVAL, QC and CAMBRIDGE, ENGLAND , May 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its first quarter ...
Liminal Biosciences to Present at Upcoming Investor Conferences
LAVAL, QC, and CAMBRIDGE, England , May 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced tha...
Liminal BioSciences Reports Fourth Quarter and Year End 2021 Financial Results
Planned Phase 1a Single Ascending Dose ("SAD") clinical trial, commencing in Q2 2022, to compare fezagepras with sodiumphenylbutyrate as a nitrogen scavenger Repayment in full of the $39.1M secured loan...
Liminal BioSciences Provides Update on Its Lead Drug Candidate Fezagepras
Analysis of PK data from Phase 1 Multi-Ascending Dose ("MAD") clinical trial completed Data observed shows that fezagepras has nitrogen scavenging properties Planned Phase 1a Single Ascending Dose ("SAD...
Liminal BioSciences Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
LAVAL, QC, and CAMBRIDGE, ENGLAND , March 7, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that on March 4, 2022, it received a wr...
Liminal BioSciences Repays its Secured Debt Ending its Creditor Relationship with Structured Alpha LP
Repayment eliminates total debt of $39.1M Early Repayment results in: Total interest savings of CA$9.1M Immediate termination of Loan Agreement and release of security interests over all of its secured ...
Liminal BioSciences Pauses Development Of Fezagepras, Outlines R&D Priorities For 2022
Following the analysis of the preliminary pharmacokinetic data from the Phase I MAD trial, Liminal BioSciences Inc (NASDAQ: LMNL) said that it would not be progressing the development of fezagepras for ...
Liminal BioSciences Announces Strategic Priorities For 2022
LAVAL, QC and CAMBRIDGE, England, Jan. 19, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today provided an update in which it outlined key corpora...
Liminal BioSciences Reports Third Quarter 2021 Financial Results
Closing of the Sale of a Rare Pediatric Disease Priority Review Vou cher for gross proceeds of USD105M Closing of the Sale of the Remaining Plasma-Derived Therapeutics Business to Kedrion S.p.A Completi...
Liminal BioSciences Inc. (LMNL) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Liminal BioSciences Inc. (LMNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Liminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics Business
LAVAL, QC and CAMBRIDGE, England, Oct. 15, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that it has closed on the sale of the rem...
Liminal BioSciences Announces Closing of Sale of Priority Review Voucher
LAVAL, QC and CAMBRIDGE, England, Sept. 28, 2021 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that its subsidiary Prometic Biotherapeu...
After Plunging 34.5% in 4 Weeks, Here's Why the Trend Might Reverse for Liminal BioSciences Inc. (LMNL)
Liminal BioSciences Inc. (LMNL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earni...
Liminal BioSciences Inc. (LMNL) Reports Q2 Loss, Misses Revenue Estimates
Liminal BioSciences Inc. (LMNL) delivered earnings and revenue surprises of 22.73% and -90.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Liminal BioSciences Reports Second Quarter 2021 Financial Results
Receipt of FDA Approval for Ryplazim® (plasminogen, human-tvmh) Receipt of a Rare Pediatric Disease Priority Review Voucher Signature of Agreement to Divest Plasma-Derived Therapeutics Business to Kedri...
Liminal BioSciences Stock Is Trading Higher On Sale Of Priority Review Voucher For $105M
Liminal BioSciences Inc's (NASDAQ: LMNL) subsidiary Prometic Biotherapeutics Inc has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $105M. The FDA granted the PRV with the a...
Liminal BioSciences Announces Sale of Priority Review Voucher for USD105M
LAVAL, QC and CAMBRIDGE, England , Aug. 9, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that, its subsidiary Prometic Biotherapeu...
Liminal BioSciences Inc. (LMNL) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Liminal BioSciences Inc. (LMNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Liminal BioSciences Announces Closing of Sale of Plasma-Derived Therapeutics Manufacturing Facility
LAVAL, QC and CAMBRIDGE, England, July 9, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced toda...
Liminal BioSciences Announces Signature of a Share Purchase Agreement for sale of Remaining Plasma-derived Business w...
LAVAL, QC and CAMBRIDGE, England, June 23, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that, Kedrion S.p.A ("Kedrion") has exerc...
Liminal Announces Voting Results of Its 2021 Annual and Special General Meeting of Shareholders (AGM)
LAVAL, QC and CAMBRIDGE, England, June 4, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General and Sp...